Has Ashley McGinnis received payments from drug or device companies?

Yes. Drug and device makers reported $8,361 in general payments to Ashley McGinnis across 493 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashley McGinnis did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashley McGinnis come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashley McGinnis

Family · Slidell, LANPI 1750629432

Payments from drug & device makers

$8,361in general payments, 2019–2025

Across 493 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
GSK$1K
Novo Nordisk$788
AstraZeneca$613
Lilly USA, LLC$574
Bayer$476
plus $4K from 32 others

What the payments were for

Food & beverage$8,344100%
Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	77	$1,048
GSK	81	$1,023
Novo Nordisk	57	$788
AstraZeneca	10	$613
Lilly USA, LLC	38	$574
Bayer	26	$476
Merck	28	$419
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	25	$403
Ironwood Pharmaceuticals, Inc	19	$362
Amgen	21	$345
Pfizer	19	$321
Supernus Pharmaceuticals, Inc.	1	$261
Stryker	2	$217
Otsuka America Pharmaceutical, Inc.	12	$201
Abbott	9	$172
Boehringer Ingelheim	9	$160
Sanofi-aventis U.S. LLC	10	$157
Amarin Pharma, Inc.	7	$136
Exact Sciences	6	$118
Johnson & Johnson	5	$65
Astellas Pharma US Inc	4	$65
Axsome Therapeutics, Inc.	2	$54
Sunovion Pharmaceuticals Inc.	4	$49
Biohaven Pharmaceuticals, Inc.	3	$42
Edwards Lifesciences	1	$40
Biohaven Pharmaceutical Holding Company Ltd.	2	$37
Sumitomo Pharma America, Inc.	2	$29
Dexcom, Inc.	1	$27
Takeda Pharmaceuticals U.S.A., Inc.	2	$25
Ardelyx, Inc.	1	$20
Amneal Pharmaceuticals LLC	1	$19
Kowa Pharmaceuticals America, Inc.	1	$18
Phathom Pharmaceuticals, Inc.	2	$15
Eisai Inc.	1	$14
Lifescan, Inc.	1	$14
Boston Scientific	1	$13
Tactile Systems Technology Inc	1	$11
Esperion Therapeutics, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,361 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024

$17,584

Medicare patients

115

Services billed

259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	77	$105,146
OzempicSemaglutide	42	$68,665
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	79	$62,076
JardianceEmpagliflozin	59	$61,016
LinzessLinaclotide	35	$25,859
JanuviaSitagliptin Phosphate	20	$21,163
FarxigaDapagliflozin Propanediol	18	$13,332
Breztri AerosphereBudesonide/Glycopyr/Formoterol	18	$11,789
MyrbetriqMirabegron	11	$10,787
Rosuvastatin Calcium	180	$2,321
Albuterol Sulfate HfaAlbuterol Sulfate	75	$1,755
Levothyroxine Sodium	158	$1,721
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	30	$1,478
Gabapentin	86	$1,288
Droplet Pen NeedlePen Needle, Diabetic	14	$1,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCMounjaro	$574	$105,14677 claims
Novo NordiskOzempic	$788	$68,66542 claims
GSKTrelegy Ellipta	$1,023	$62,07679 claims
Boehringer IngelheimJardiance	$160	$61,01659 claims
AbbVieLinzess, Synthroid	$1,048	$26,68453 claims
AstraZenecaFarxiga, Breztri Aerosphere	$613	$25,12136 claims
MerckJanuvia	$419	$21,16320 claims
Astellas Pharma US IncMyrbetriq	$65	$10,78711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium	$19	$1,721158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.